Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100720 | 1.00 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL27377888 | 0.82 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL1347469 | 0.81 | BRD4 (0.55) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL13007537 | 0.78 | SIRT2 (0.45) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL257552 | 0.77 | ALDH1A1 (0.62) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL6968655 | 0.77 | ALDH1A1 (0.62) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL18743294 | 0.76 | ACHE (0.49) | ALDH1A1 | |
| SCHEMBL434007 | 0.76 | ACHE (0.49) | ALDH1A1 | |
| SCHEMBL16333559 | 0.76 | ALDH1A1 (0.42) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL14550603 | 0.75 | BRD4 (0.51) | PNMTADRA2AADRA2BADRA2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| WO-2021151062-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERISTY (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2013027168-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | PFIZER INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20050165006-A1 | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same | HYUNDAI PHARM. IND. CO., LTD. (KR) | 2005-07-28 | — | — | US | disclosed |
| WO-2003082286-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHEMON INC. (KR) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165006-A1 | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same | SLC18A2, SLC6A4, SLC6A2 | PNMT 323/4885ADRA2A 274/4885ADRA2B 246/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | PNMT 1641/4885ADRA2A 1558/4885ADRA2B 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.